Company intelligence / Profile preview

Kinnate Biopharma Inc.

San Diego, California, United Stateskinnate.com ↗

Ownership: Public · KNTE
Development stage: Phase 1

Overview

Kinnate Biopharma was a precision oncology company developing small molecule kinase inhibitors for difficult-to-treat cancers with genetic alterations. The company was acquired by XOMA Corp in April 2024.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

exarafenib

Phase 1

Indications: BRAF-mutant solid tumors, NRAS-mutant melanoma

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $125M
Total revenue: $0
Enterprise value: $-25.9M

Beyond the preview

Go deeper on Kinnate Biopharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kinnate Biopharma Inc..

Explore the full profile